Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 19/20 | 0.68 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MPI | P34949 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4225477 | 0.91 | MAPK14 (0.64) | MAPK14 | |
| SCHEMBL4224566 | 0.85 | MAPK14 (0.60) | MAPK14MAPTSMN1; SMN2 | |
| SCHEMBL4220066 | 0.84 | MAPK14 (0.74) | MAPK14 | |
| SCHEMBL4226941 | 0.82 | MAPK14 (0.68) | MAPK14 | |
| SCHEMBL4217396 | 0.81 | MAPK14 (1.00) | MAPK14 | |
| SCHEMBL2314885 | 0.81 | MAPK14 (0.57) | MAPK14 | |
| SCHEMBL13890762 | 0.79 | MAPK14 (0.71) | MAPK14 | |
| SCHEMBL4220120 | 0.78 | MAPK14 (0.81) | MAPK14 | |
| SCHEMBL4217780 | 0.78 | PTPRC (0.51) | MAPK14NPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL4219691 | 0.78 | MAPK14 (0.74) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105327-A1 | Dibenzocycloheptane compounds and pharmaceuticals containing these compounds | MERCKLE GMBH (DE) | 2009-04-23 | — | — | US | disclosed |
| US-20090105327-A1 | Dibenzocycloheptane compounds and pharmaceuticals containing these compounds | MERCKLE GMBH (DE) | 2009-04-23 | — | — | US | disclosed |
| EP-1881968-A2 | DIBENZOCYCLOHEPTANE COMPOUNDS AND PHARMACEUTICALS CONTAINING THESE COMPOUNDS | MERCKLE GMBH (DE) | 2008-01-30 | — | — | EP | disclosed |
| WO-2006120010-A2 | DIBENZOCYCLOHEPTANE COMPOUNDS AND PHARMACEUTICALS CONTAINING THESE COMPOUNDS | MERCKLE GMBH (DE) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105327-A1 | Dibenzocycloheptane compounds and pharmaceuticals containing these compounds | BDKRB1, IL1R1, IL1A | MAPK14 3479/4885NPC1 668/4885ALDH1A1 420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.